Press Releases
2025
- June 19 Announcement of Results of the Tender Offer for Our Shares by Shionogi & Co., Ltd. and Changes in an Other Associated Company and a Major Shareholder（PDF）
- June 05 (Amendment) Partial amendments to the “Announcement of Expression of Opinion in Support of the Tender Offer for Our Shares by Shionogi & Co., Ltd. and Recommendation to Tender Shares in the Tender Offer”（PDF）
- June 05 Our Relationship with Patent Infringement Lawsuit regarding Drug Use Patent Pertaining to Oral Antipruritus Medication “REMITCH ® ” announced by Toray Industries, Inc. on May 27, 2025（PDF）
- May 14 Top-line Results of Bioequivalence Study between JTE-052 Lotion and Ointment, JAK Inhibitor, in Patients with Atopic Dermatitis in Japan（PDF）
- May 7 Announcement of Expression of Opinion in Support of the Tender Offer for Our Shares by Shionogi & Co., Ltd. and Recommendation to Tender Shares in the Tender Offer（PDF）
- May 7 Notice Regarding Revision of the Interim and Year-end Dividend Forecasts (Nil Dividend) for the Fiscal Year Ending December 2025（PDF）
- February 7 Torii has announced Medium-Term Management Plan 2025-2027（PDF）
- February 7 Announcement Regarding Changes of Representative Director and Officers（PDF）
2024
- December 6 Torii Files New Drug Application of TO-208 for the Treatment of Molluscum Contagiosum in Japan（PDF）
- August 15 Listing on the Japanese National Health Insurance Drug Price List and Launch of VTAMA® Cream 1% in Japan（PDF）
- June 24 JT Receives Manufacturing and Marketing Approval of VTAMA® Cream 1% for the Treatment of Atopic Dermatitis and Plaque Psoriasis in Japan（PDF）
- May 31 Positive Top-line Results of Phase 3 Clinical Study (Comparative Study) of JTE-061 (tapinarof) Cream, Aryl hydrocarbon Receptor (AhR) agonist, in Pediatric Patients with Atopic Dermatitis in Japan（PDF）
- March 15 Torii’s Views on Report from ISS, a Proxy Advisory Firm, On Proposals for Torii’s General Meeting of Shareholders（PDF）
- February 16 Notice of the Opinion of the Board of Directors Regarding the Shareholder Proposal（PDF）
- February 16 Notice of Notification Regarding the Partial Withdrawal of the Shareholder Proposal（PDF）
- February 9 Torii has announced updated numerical targets of Medium-/Long-Term Business Vision "VISION2030" and Medium-Term Management Plan 2024-2026（PDF）
2023
- December 15 Top-line Results of Phase 3 Clinical Study of TO-208 for the Treatment of Molluscum Contagiosum in Japan（PDF）
- December 13 Signing of an Agreement for the Exclusive Development and Commercialization of GRAZAX®,an Allergen Immunotherapy (Sublingual Immunotherapy) Drug for Grass Pollinosis in Japan（PDF）
- November 8 Announcement regarding Transition to Company with Audit and Supervisory Committee,and Changes of Representative Director and Officers（PDF）
- September 15 JT Files New Drug Application of JTE-061 Cream,Aryl hydrocarbon Receptor (AhR) agonist,for the Treatment of Atopic Dermatitis and Plaque Psoriasis in Japan（PDF）
- March 16 Torii’s Views on Report from ISS, a Proxy Advisory Firm, On Proposals for Torii’s General Meeting of Shareholders（PDF）
- February 17 Notice of the Opinion of the Board of Directors Regarding the Shareholder Proposal（PDF）
- February 10 Torii has announced Medium-Term Management Plan 2023-2025（PDF）
- January 26 Torii has entered into License Agreement with Nogra Pharma Limited to Develop & Commercialize NAC-GED-0507 in Japan（PDF）
Older press releases can be found in the Back Number.